

9° WORKSHOP IN EMATOLOGIA TRASLAZIONALE DELLA SOCIETÀ ITALIANA DI EMATOLOGIA SPERIMENTALE Bologna, Aula "G. Prodi", 19-20 maggio 2025



Elucidating the role of clonal hematopoiesis in myeloid neoplasms secondary to germline predisposition. Enrico Attardi, MD PhD Department of Biomedicine University of Rome Tor Vergata

Disclosures di Enrico Attardi

Company name	Research support	Employee	Consultant	Stockholder	Speakers bureau	Advisory board	Other

Surveillance in BMFS and leukemia predisposition

No unique consensus for surveillance of patients with MDS/AML predisposing conditions



Study design and Methods

Clinical NGS assay

- Limit of detection: 3% for SNVs and 1% for small insertions or deletions less than 24 base pairs
- 68 gene myeloid malignancy panel

CytoScan(TM) HD Suite (ThermoFisher)

- 2.67 million markers across the genome
- Limit of detection of mosaicism: 20-30%

Patient characteristics	n=165	
Male/Female	81/84	
Median age at diagnosis (range)	6.2 (0-20.4) years	
Median age at first determination (IQR)	10.6 (6.7-16.0) years	
Inherited bone marrow failure syndromes (%)	77 (46.7)	
Aplastic anemia (%)	34 (20.6)	
Other cytopenia (%)	54 (32.7)	
Patients with paired BM/PB samples for NGS analysis, n (%)	71 (43.0)	
Patients with paired BM/PB samples for SNP-A analysis, n (%)	67 (40.6)	



The landscape of clonal events



-SAMD9/9L syndromes had the highest frequency of somatic alterations (12/14 pts, 85.7%). -PIGA_{mut} and UPD6p had 100% positive predictive value (PPV) for AA diagnosis.

-Novel CH events:

- subclonal UPD2p25 in germline RPS7-mutated Diamond Blackfan anemia → somatic rescue
- somatic *CBL*_{mut} in germline *RPL15*-mutated Diamond Blackfan anemia

→ uncertain significance

Differences between BM and PB clones by NGS



Test agreement

(Cohen's Kappa method)

Mutation concordance



PB testing showed a sensitivity of 92.9% and a specificity of 97.9%

NGS-testing on PB is a robust source for detection of clonal hematopoiesis

Differences between BM and PB clones by NGS



- $CSF3R_{mut}$: VAF \uparrow in PB
- BCOR_{mut}: VAF 个 in BM
- Major discrepancies involved SAMD9/9L_{mut} (clones can be selectively confined to either the myeloid or lymphoid compartment)

Differences between BM and PB clones by SNP-A





Mutation concordance

SNP-A on PB may lose essential clonal events detected in BM

Utility of NGS and SNP-A implementation for clinical decision-making

= Bone marrow

 ∇ = Peripheral blood



Shwachman-Diamond syndrome

Somatic testing can early predict the leukemic transformation in BMFS

Implications of genomic profiling for surveillance and timing of transplantation



High-risk leukemia

Somatic testing on PB improve long-term surveillance in BMFS/AA and guide timely clinical interventions

9° WORKSHOP IN EMATOLOGIA TRASLAZIONALE DELLA SOCIETÀ ITALIANA DI EMATOLOGIA SPERIMENTALE

St. Jude Childrens' Research Hospital



St. Jude Children's Research Hospita Finding carel: Sector childler





Wlodarski Lab Marcin W. Wlodarski Sushree Sahoo Masanori Yoshida Damian Krzyzanowski Swarna Beesetti Lili Kotmayer

BMF Clinical Team Nathan Gray **Clifford Takemoto Rohith Jesudas Georgios Christakopoulos Richa Sharma** Senthil Bhoopalan Sara Lewis Michelle Boals

Department of Biostatistics

Guolian Kang

ARUP Laboratories

Peng Li Frica F. Andersen lian 7hao Lucilla Pizzo **Bo Hong**



Maria Teresa Voso Beatrice Borsellino Mariadomenica Divona Emiliano Fabiani Giulia Falconi Luca Guarnera Carmelo Gurnari Nicole Lelli Eleonora Lumia Tiziana Ottone Eugenia Ricci **Giorgia Silvestrini**

UOSD Laboratorio di Diagnostica Avanzata Oncoematologica «Francesco Lo Coco»

Immunologia pediatrica

Caterina Cancrini Gigliola Di Matteo Viviana Moschese Paolo Palma

Genetica medica

Federica Carla Sangiuolo Enrica Marchionni Valentina Ferradini



BMF/MDS Program Bone Marrow Failure and Myelodysplastic Syndromes.

EUROPEAN JOINT RARE DISEASES

IAZIONE ITALIAN CONTRO LEUCEMIE



